Utdanning
- Hovedfag ved Matematisk institutt, avdeling for statistikk, Universitetet i Oslo (1997)
- Doktorgrad (PhD) ved Institutt for medisinske basalfag, avdeling for biostatistikk, Universitetet i Oslo (2008)
Stilling
- Seniorforsker, Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet Sykehus
Interessefelt
- Kliniske studier og design
- Dataanalyse
- Programmering
- Maskinlæring
E-post
Besøksadresse
Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo
Postadresse
Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo
Prosjekter
WP1 - Behandlingsstudier
ARCTIC
Remisjon hos pasienter med revmatoid artritt: en randomisert kontrollert studie som undersøker bruk av ultralyd i klinisk oppfølging
Prosjektleder:
Espen A. Haavardsholm
WP1 - Behandlingsstudier
ARCTIC REWIND
10-års oppfølging av pasienter med revmatoid artritt som mottok strukturert behandling-til-mål-terapi i tidlig sykdomsfase.
Prosjektleder:
Espen A. Haavardsholm
WP4 - Håndtering av tilleggssykdommer
ExeHeart
Bedre hjertekar helse for pasienter med inflammatorisk leddsykdom
Prosjektleder:
Anne Therese Tveter
WP5 - Strategier for digital oppfølging
NOR-Flare
Avstandsoppfølging av pasienter med revmatoid artritt
Prosjektleder:
Anne Therese Tveter
WP2 - Presisjonsmedisin
Nor-vaC
Immunologisk respons på COVID-19 vaksine hos pasienter på immunosuppressiv behandling
Prosjektleder:
Guro Løvik Goll
WP5 - Strategier for digital oppfølging
ReMonit
Digital hjemmeoppfølging av pasienter med spondyloartritt
Prosjektleder:
Nina Østerås
WP5 - Strategier for digital oppfølging
ReMonit Gout
Digital hjemmeoppfølging og mestring av urinsyregikt
Prosjektleder:
Nina Østerås
WP1 - Behandlingsstudier
SQUEEZE
Maksimering av effekten av reseptbelagte legemidler ved revmatoid artritt
Prosjektleder:
Espen A. HaavardsholmPublikasjoner
Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
Kaja Eriksrud Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad
The Lancet Rheumatology
2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Marthe Kirkesæther Brun, Johanna Gehin, Kristin Reine Hammersbøen, David Warren, Rolf Klaasen, Joseph Sexton
The Lancet Rheumatology
2024
Does follow-up really matter? A convergent mixed methods study exploring follow-up across levels of care in rehabilitation of patients with rheumatic and musculoskeletal diseases
Gunnhild Berdal, Anne-Lene Sand-Svartrud, Anita Dyb Linge, Ann Margret Aasvold, Kjetil Tennebø, Siv Grødal Eppeland
Disability and Rehabilitation
2024
Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: results from an international collaboration
Celina K. Gehringer, Glen P. Martin, Kimme L. Hyrich, Suzanne M.M. Verstappen, Joseph Sexton, Eirik Kristianslund
Journal of Clinical Epidemiology
2024
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen
RMD Open
2024
Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial
Inger Jorid Berg, Anne Therese Tveter, Gunnstein Bakland, Sarah Hakim, Eirik Kristianslund, Siri Lillegraven
JMIR Research Protocols
2023
Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
Helga Westerlind, Bente Glintborg, Hilde Berner Hammer, Saedis Saevarsdottir, Niels Steen Krogh, Merete Lund Hetland
RMD Open
2023
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Lexberg
Annals of the Rheumatic Diseases
2023
Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods
Hilde Berner Hammer, Sigve Lars Pedersen, Maria Karolina Jonsson, Linda Mathsson-Alm, Isabel Gehring, Joseph Sexton
Scandinavian Journal of Clinical and Laboratory Investigation
2023
Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Daniel H. Solomon, Désirée Van Der Heijde
Journal of the American Medical Association (JAMA)
2023
Associations between cardiovascular risk factors, disease activity and cardiorespiratory fitness in patients with inflammatory joint disease: a cross-sectional analysis
Kristine Røren Nordén, Anne Grete Semb, Hanne Dagfinrud, Jonny Hisdal, Sigrid Ødegård, Joseph Sexton
BMC sports science, medicine and rehabilitation
2023
Bridging gaps across levels of care in rehabilitation of patients with rheumatic and musculoskeletal diseases: Results from a stepped-wedge cluster randomized controlled trial
Gunnhild Berdal, Anne-Lene Sand-Svartrud, Anita Dyb Linge, Ann Margret Aasvold, Kjetil Tennebø, Siv Grødal Eppeland
Clinical Rehabilitation
2023
Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit
Anne Grete Semb, Silvia Christin Hellerud Rollefstad, Joseph Sexton, Eirik Ikdahl, Cynthia S. Crowson, Piet van Riel
International journal of cardiology: Heart and Vasculature (IJCHA)
2022
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
Silvia Christin Hellerud Rollefstad, Eirik Ikdahl, Grunde Wibetoe, Joseph Sexton, Cynthia S. Crowson, Piet van Riel
European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy
2022
Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data
Vibeke Norvang, Espen A. Haavardsholm, Sara K. Tedeschi, Houchen Lyu, Joseph Sexton, Maria Dahl Mjaavatten
BMC Medical Research Methodology
2022
Effect of high-intensity exercise on cardiorespiratory fitness, cardiovascular disease risk and disease activity in patients with inflammatory joint disease: Protocol for the ExeHeart randomised controlled trial
Kristine Røren Nordén, Hanne Dagfinrud, Anne Grete Semb, Jonny Hisdal, Kirsten Kilvik Viktil, Joseph Sexton
BMJ Open
2022
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.
Johanna Elin Gehin, Silje Watterdal Syversen, David Warren, Guro Løvik Goll, Joseph Sexton, Nils Bolstad
RMD Open
2021
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Reine Hammersbøen
Journal of the American Medical Association (JAMA)
2021
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.
Mike Oliver Becker, Rucsandra Dobrota, Alexandru Garaiman, Rudolf Debelak, Kim Fligelstone, Ann Tyrrell Kennedy
Annals of the Rheumatic Diseases
2021
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Johanna Elin Gehin, David Warren, Silje Watterdal Syversen, Elisabeth Lie, Joseph Sexton, Liz Paucar Loli
Scandinavian Journal of Rheumatology
2021
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Ingrid Egeland Christensen, Siri Lillegraven, Mielnik Pawel, Gunnstein Bakland, Liz Paucar Loli, Joseph Sexton
Annals of the Rheumatic Diseases
2021
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target
Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tove Borgen, Espen A. Haavardsholm, Tore Kristian Kvien
RMD Open
2021
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Siri Lillegraven, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad
Journal of the American Medical Association (JAMA)
2021
Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-To-Target strategy
Ulf Gunnar Sundin, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Lena Kristine Bugge Nordberg, Hilde Berner Hammer
RMD Open
2021
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Øystein Sandanger, Joseph Sexton, Inge Christoffer Olsen
Journal of the American Medical Association (JAMA)
2021
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
Brigitte Michelsen, Ulf Lindström, Catalin Codreanu, Adrian Ciurea, Jakub Zavada, Anne Gitte Loft
RMD Open
2020
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)
Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Øystein Sandanger, Johanna Elin Gehin
Trials
2020
Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis
Hilde Berner Hammer, Brigitte Michelsen, Joe Sexton, Till Uhlig, Sella Aarrestad Provan
Clinical Rheumatology
2020
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Johanna Elin Gehin, Guro Løvik Goll, David John Warren, Silje Watterdal Syversen, Joseph Sexton, Eldri Kveine Strand
Arthritis Research & Therapy
2019
Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials
Lene Terslev, Robin Christensen, Anna-Birgitte Aga, Joseph Sexton, Espen A. Haavardsholm, Hilde Berner Hammer
Arthritis Research & Therapy
2019
Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis
Hilde Berner Hammer, Brigitte Michelsen, Joseph Sexton, Ida Kristin Haugen, Sella Aarrestad Provan, Espen A. Haavardsholm
Annals of the Rheumatic Diseases
2019
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial
Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Inge Christoffer Olsen, Nils Bolstad, Espen A. Haavardsholm
Journal of Internal Medicine
2019
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
Lena Kristine Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Elisabeth Lie
RMD Open
2018
Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?
Brigitte Michelsen, Joseph Sexton, Josef Sebastian Smolen, Daniel Aletaha, Niels Steen Krogh, Desirée van der Heijde
Annals of the Rheumatic Diseases
2018
DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs
Silva Pukšić, Pernille Bolton-King, Joseph Sexton, Brigitte Michelsen, Tore Kristian Kvien, Hilde Berner Hammer
RMD Open
2018
Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTICstudy
Karen Holten, Joseph Sexton, Tore Kristian Kvien, Anna-Birgitte Aga, Espen A. Haavardsholm
RMD Open
2018
The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyses from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen
Lena Kristine Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, Joseph Sexton, Elisabeth Lie, Hilde Berner Hammer
Arthritis & Rheumatology
2018
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy
Maria Karolina Jonsson, Aase Haj Hensvold, Monika Hansson, Anna-Birgitte Aga, Joseph Sexton, Linda Mathsson-Alm
Arthritis Research & Therapy
2018
Health-related quality of life in patients with psoriatic and rheumatoid arthritis: Data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls
Brigitte Michelsen, Till Uhlig, Joseph Sexton, Desirée van der Heijde, Hilde Berner Hammer, Eirik Kristianslund
Annals of the Rheumatic Diseases
2018
Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study
Brigitte Michelsen, Eirik Kristianslund, Joseph Sexton, Hilde Berner Hammer, Karen Minde Fagerli, Elisabeth Lie
Annals of the Rheumatic Diseases
2017